Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for untreated advanced hepatocellular carcinoma.
Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab for untreated advanced hepatocellular carcinoma [ID1248] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1248

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 November 2022 Discontinued. Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab for untreated advanced hepatocellular carcinoma [ID1248] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
05 February 2021 The Department for Health and Social Care has asked NICE to carry out an appraisal of nivolumab for untreated advanced hepatocellular carcinoma. For information, the company have announced that their trial did not meet its primary endpoint and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes
16 April 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab for untreated advanced hepatocellular carcinoma. Please note that following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. NICE will continue to monitor any development and will update interested parties as and when the situation changes.
16 April 2020 Suspended. Topic is suspended
08 April 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for untreated advanced hepatocellular carcinoma. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.
12 October 2018 Following an update from the company, NICE has rescheduled the appraisal and it is expected to begin in late March 2019.
09 May 2018 - 07 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual